Neurocrine Biosciences, Inc. Share Price & Technical Analysis
NBIX · $156.6 (-0.04%)
Healthcare / Drug Manufacturers - Specialty & Generic
$156.6
-0.04%
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSI…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
19% return in May, 0% avg return in past 3 year May month.
14% return in 2026, 8% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -4% | -2% | 1% | 0% | 19% | – | – | – | – | – | – | – | 14% |
| 25 | 11% | -20% | -7% | -3% | 14% | 2% | 2% | 10% | 1% | 2% | 7% | -7% | 12% |
| 24 | 7% | -7% | 5% | 0% | -3% | 2% | 3% | -15% | -9% | 5% | 5% | 8% | 0% |
| 23 | -7% | -6% | -1% | -1% | -12% | 5% | 8% | 6% | 3% | -2% | 5% | 13% | 11% |
| 22 | -8% | 15% | 5% | -4% | 4% | 3% | -3% | 11% | 2% | 8% | 11% | -6% | 37% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Strong
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$15.53B
P/E ratio
23.8
52W high
$162.4
52W low
$119.6
Volume
4,53,283
Beta
0.34
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Neurocrine Biosciences, Inc. share price today?
- Neurocrine Biosciences, Inc. (NBIX) last traded around $156.6 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does NBIX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for NBIX. Download the app for real-time alerts.
- How can I analyze Neurocrine Biosciences, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.